Navigation Links
Mast Therapeutics Announces Management Change
Date:8/29/2014

SAN DIEGO, Aug. 29, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), an emerging biopharmaceutical company, announced today that Santosh Vetticaden, Chief Medical Officer and Senior Vice President, will be leaving the Company, for personal reasons, in mid-September.  Edwin L. Parsley, D.O., the Chief Medical Officer of Aires Pharmaceuticals, which Mast acquired earlier this year, will assume Dr. Vetticaden's former responsibilities as the Company's interim Chief Medical Officer.  Dr. Parsley previously was with Pfizer, where he oversaw clinical trials for Revatio® (sildenafil).  He is a practicing physician and certified by the American Board of Internal Medicine in internal medicine, pulmonary disease, critical care medicine, and sleep medicine.  Dr. Parsley has been actively engaged with the Company since Aires was acquired by Mast in February 2014. 

"We want to thank Santosh for his many contributions and wish him the very best in his future endeavors," said Brian Culley, Chief Executive Officer. "Santosh has put in place a strong clinical operations group that has us well-positioned to advance our programs through late-stage development.  In addition to executing a successful QT study last year, his team is actively recruiting patients in EPIC, our pivotal Phase 3 study, at more than 50 U.S. and international sites. They are also actively recruiting patients in our Phase 2 combination study with MST-188 and r-tPA in acute limb ischemia, and have us poised to launch a third clinical study in heart failure next year.  Santosh accomplished much during his tenure and leaves us with the people and infrastructure to achieve four clinical study read-outs over the next 12 to 18 months."

About Mast Therapeutics

Mast Therapeutics, Inc. is a publicly traded bio
'/>"/>

SOURCE Mast Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... HAIKOU, China , April 22 /PRNewswire-Asia-FirstCall/ ... (OTC Bulletin Board: KURU), a,leading bio-pharmaceutical company in ... peptide-based drugs and small molecule drugs, today,announced the signing ... of preferred stock and warrants with Caduceus Asia ...
... CardioGenics Inc. (OTC Bulletin Board: CGNH), a developer of technology and ... spotlighted in three publications during the month of April: Today,s Medical ... Transcript . , , ... the April 2010 print and online editions of Today,s ...
Cached Medicine Technology:Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 2Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 3Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 4CardioGenics to be Spotlighted in Three Publications During Month of April 2CardioGenics to be Spotlighted in Three Publications During Month of April 3CardioGenics to be Spotlighted in Three Publications During Month of April 4
(Date:12/19/2014)... TX (PRWEB) December 20, 2014 The ... a new injectable filler from respected cosmetic brand Juvéderm. ... occur naturally with age. The Medspa at Hendrick is ... development in skin care technology to its clients. , ... gel to be FDA-approved to treat the mid-face and ...
(Date:12/19/2014)... (HealthDay News) -- All children should have their eyesight ... every year, eye experts say. The new vision-screening ... of the U.S. National Center for Children,s Vision Health. ... group require screening for eye problems, particularly vision ... ("lazy eye") and strabismus (a disorder of eye alignment). ...
(Date:12/19/2014)... -- The cost of cancer treatment can cause financial ... Researchers examined data from 1,000 people in the ... lung cancer. Of those patients, almost 900 had finished ... had advanced cancer. Nearly half of the patients ... which was linked with a poorer health-related quality of ...
(Date:12/19/2014)... Dennis Thompson HealthDay ... -- Ebola,s entrance into the United States -- along ... mumps outbreak -- have highlighted cracks in the nation,s ... new health policy report released Thursday. Half of ... respond to infectious disease outbreaks. That was the main ...
(Date:12/19/2014)... NJ (PRWEB) December 19, 2014 ... Inside Patient Care: Pharmacy & Clinics™, an independent ... healthcare team treating and caring for patients inside ... primary care expands to provide optimal access to ... offers a forum for the team treating and ...
Breaking Medicine News(10 mins):Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3
... People who suffer from the problem of excessive sweating ... have a relief from their condition. Researchers from Saint ... treatment with Botox (botulinum toxin type A) could be ... the first long-term study of repeated treatment with Botox? ...
... like learning and impulsive behavior.// ,The research, ... said that it would help shed light on the impulsive ... and his team at the University of Pittsburgh, Pennsylvania, who ... of the brain in a group of rats to examine ...
... a recent study researchers say that latest research suggests ... be ineffective for women who lack a gene called ... fertility drugs did not improve ovulation rates in mice ... The estrogen receptor beta is one of two estrogen ...
... school children from Denmark, Estonia and Portugal// reported that ... compared to children from children’s of rich and better-educated ... British Medical Journal. The results of the study challenge ... social circumstances in childhood may cause an increased risk ...
... how the heart fails, and hope that this may make ... worked to find out how the metabolic pathways differentiate in ... early stages of heart failure, the heart uses too much ... doesn't use enough fat., ,Gary Lopaschuk, a pharmacologist and ...
... registers its win against polio as the number of cases //reported ... the year 2002. , ,UNICEF, and an army of health ... leading the war against polio in India. Of the 1918 ... India alone, and 1242 cases were registered in Uttar Pradesh. This ...
Cached Medicine News:Health News:Good News For Those Suffering From Excessive Sweating 2Health News:Good News For Those Suffering From Excessive Sweating 3Health News:Regular Use Of Cocaine Can Impair Brain Functions 2Health News:New Discovery May Help Treat Infertility 2Health News:Details Of Heart Failure Discovered 2Health News:Intense Fight Against Polio In India Gets Results 2
... Tupos LA, the only ICD system ... is the first implant for the treatment ... from a lasting improvement of their hemodynamics ... Tupos LA uses biatrial stimulation to effectively ...
... II Marquis incorporates the latest advances ... resynchronization benefits include separately programmable ventricular ... unique patient needs. Also included are ... physicians manage heart failure patients who ...
... DAPII brain biopsy needle guide housing. ... Screw mount. Placed through a ... Non-sterile; sterilize via autoclave Guide sphere assembly ... with biopsy needles with barium sleeves. Sterile; ...
... The Double Bundle PCL Guides were ... femoral tunnels necessary in arthroscopic double bundle ... placement for anterolateral and posteromedial femoral tunnel ... , ,During anterolateral tunnel placement a guide ...
Medicine Products: